ARTICLE | Emerging Company Profile
German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads
By Danielle Golovin, Senior Biopharma Analyst
June 5, 2024 10:07 PM UTC
Tubulis is innovating on the linker, payload and drug-to-antibody ratio of antibody-drug conjugates, with a modular platform that optimizes for ADC stability and allows tailoring to each target.
Munich-based Tubulis GmbH raised €128 million ($140 million) in a series B2 round in March, co-led by EQT Life Sciences and Nextech Invest, bringing the total amount raised by the company to about $215 million…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652551/tubulis-enhancing-adc-stability-via-new-conjugation-methods